2015


To access this material please log in or register

Register Authorize
2015/№2

Clinico-economy analysis of the use of ivabradine for treatment of chronic heart failure

Petrov V. I., Nedogoda S. V., Sabanov A. V.
State Budgetary Educational Institution of Higher Professional Education, "Volgograd State Medical University" of the RF Ministry of Health Care, Ploshchad Pavshikh Boytsov 1, Volgograd 400131

Keywords: ivabradine, treatment, CHF

DOI: 10.18087/rhfj.2015.2.2062

A comprehensive clinico-economy analysis of the use of ivabradine for CHF treatment was performed for patients with reduced LV EF. Ivabradine clinical efficacy was evaluated by results of a clinical study SHIFT and its substudy SHIFT-PRO. Pharmacological evaluation was performed using the “cost-usefulness” and cost-effectiveness” methods and also by comparative estimation of the cost required to prevent one fatal outcome and the expenses related with this outcome. The analysis took into account the direct cost of drug therapy and hospitalization.
  1. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372 (9641):807–16.
  2. Borer JS, Bohm M, Ford I et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol. 2014 Feb 1;113 (3):497–503.
  3. Мареев В. Ю. Фармако-экономическая оценка использования ИАПФ в амбулаторном лечении больных сердечной недостаточностью (ФАСОН). Журнал Сердечная Недостаточность. 2002;3 (1):38–9.
  4. Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распростра­ненность хронической сердечной недостаточности в Европей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):112–5.
  5. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» 91500.14.0001–2002.
  6. Государственный реестр лекарственных средств. Доступно на: http://grls.rosminzdrav.ru / pricelims.aspx
  7. Göhler A, Geisler BP, Manne JM et al. Utility estimates for decision-analytic modeling in chronic heart failure – health states based on New York Heart Association classes and number of rehospita­lizations. Value in Health. 2009 Jan-Feb;12 (1):185–7.
  8. Yao G, Freemantle N, Calvert MJ et al. The long-term cost-effectiveness of cardiac resychronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42–51.
  9. Ягудина Р. И., Куликов А. Ю., Литвиненко М. М. QALY: история, методология и будущее метода. Фармакоэкономика. Современная фармакоэкономикаы и фармакоэпидемиология. 2010;3 (1):7–11.
  10. Быков А. А. О методологии экономической оценки жизни среднестатистического человека (пояснительная записка). Проблемы анализа риска. 2007;4 (2):178–91.
Petrov V. I., Nedogoda S. V., Sabanov A. V. Clinico-economy analysis of the use of ivabradine for treatment of chronic heart failure. Russian Heart Failure Journal. 2015;16 (2):119–124

To access this material please log in or register

Register Authorize
Ru En